Castle Biosciences to Participate in Upcoming Investor Conferences
Castle Biosciences (Nasdaq: CSTL), a healthcare diagnostics company, announced its participation in three upcoming investor conferences in September 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Castle Biosciences (Nasdaq: CSTL), a healthcare diagnostics company, announced its participation in three upcoming investor conferences in September 2025. The company will present at Baird's 2025 Global Healthcare Conference on September 10 at 10:15 a.m. Eastern time, with a live webcast available on their investor relations website.
Additionally, Castle's management will be available for one-on-one meetings during the Wells Fargo Healthcare Conference on September 4 and the Lake Street Best Ideas Growth Conference on September 11. Meeting requests must be coordinated through Wells Fargo and Lake Street Capital Markets.
Details
News Market Reaction – CSTL
On Aug 21, the day this news came out, CSTL closed 0.96% above the previous close.
Data tracked by StockTitan Argus for the Aug 21 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FRIENDSWOOD, Texas, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at Baird’s 2025 Global Healthcare Conference on Wednesday, Sept. 10, 2025, at 10:15 a.m. Eastern time.
A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at ir.castlebiosciences.com/events-presentations/. A replay of the webcast will be available following the conclusion of the live broadcast.
Castle will also be available for one-on-one investor meetings during the Wells Fargo 20th Annual Healthcare Conference on Sept. 4, 2025, and the 9th Annual Lake Street Best Ideas Growth (BIG9) Conference on Sept. 11, 2025. Meetings may be requested exclusively through Wells Fargo and Lake Street Capital Markets.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
Allison Marshall
amarshall@castlebiosciences.com
Source: Castle Biosciences Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.